{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:06:00Z","timestamp":1780524360075,"version":"3.54.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/inf.0000000000000327","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T11:25:27Z","timestamp":1397129127000},"page":"760-766","source":"Crossref","is-referenced-by-count":33,"title":["Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age"],"prefix":"10.1097","volume":"33","author":[{"given":"Fiona","family":"McQuaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Snape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa M.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Houlden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merryn","family":"Voysey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Dull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-19-20210202","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R3-19-20210202","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R4-19-20210202","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"R5-19-20210202","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"R6-19-20210202","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/INF.0b013e31829cfff2","article-title":"Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.","volume":"32","author":"Snape","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R7-19-20210202","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"R9-19-20210202","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/adc.2009.180596","article-title":"Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers.","volume":"96","author":"Jackson","year":"2011","journal-title":"Arch Dis Child"},{"key":"R10-19-20210202","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"R11-19-20210202","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/archdischild-2012-303103","article-title":"Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.","volume":"98","author":"Pollard","year":"2013","journal-title":"Arch Dis Child"},{"key":"R12-19-20210202","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/CVI.05655-11","article-title":"Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction.","volume":"19","author":"Ishola","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"R13-19-20210202","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"R15-19-20210202","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.","volume":"50","author":"Perrett","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R16-19-20210202","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R17-19-20210202","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1128\/CVI.00279-08","article-title":"Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.","volume":"15","author":"Trotter","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"R19-19-20210202","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R20-19-20210202","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"issue":"suppl 2","key":"R21-19-20210202","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"R22-19-20210202","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4161\/hv.18500","article-title":"Bexsero: a multicomponent vaccine for prevention of meningococcal disease.","volume":"8","author":"Gorringe","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R23-19-20210202","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","article-title":"Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.","volume":"30","author":"Ladhani","year":"2012","journal-title":"Vaccine"},{"key":"R25-19-20210202","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"issue":"suppl 2","key":"R26-19-20210202","doi-asserted-by":"crossref","first-page":"B67","DOI":"10.1016\/j.vaccine.2011.12.126","article-title":"The challenge of post-implementation surveillance for novel meningococcal vaccines.","volume":"30","author":"Snape","year":"2012","journal-title":"Vaccine"},{"key":"R30-19-20210202","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4161\/hv.18650","article-title":"Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 1 schedule in infancy.","volume":"8","author":"Ferrera","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R31-19-20210202","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.inf.0000250689.09396.21","article-title":"Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.","volume":"26","author":"Vesikari","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R32-19-20210202","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b3 randomised, observer-blind, placebo-controlled study.","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"R33-19-20210202","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","article-title":"Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"R34-19-20210202","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2007.01.022","article-title":"Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.","volume":"25","author":"Nokleby","year":"2007","journal-title":"Vaccine"},{"key":"R35-19-20210202","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/INF.0b013e31829aa63b","article-title":"A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups.","volume":"32","author":"Hoiseth","year":"2013","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:03:29Z","timestamp":1620954209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201407000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000327","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}